A single compound capable of dampening GSK3β activity while boosting SIRT1 function could theoretically deliver a “one-two punch” against AD: concurrently reducing toxic tau phosphorylation and related neurodegeneration via GSK3β inhibition and enhancing neuronal survival pathways and proteostasis via SIRT1 activation. This evidence concerns the gene MAPT and Alzheimer disease.